From established players to up-and-coming firms, Canada’s pharmaceutical landscape is diverse and dynamic. Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well. Read on to learn about what’s been driving the share prices of the best-performing Canadian pharma stocks. 1. HLS Therapeutics (TSX:HLS) Year-on-year gain: 26.6 percentMarket cap: C$149.8 millionShare price: C$4.76 HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia. HLS in-licensed the exclusive rights to the treatments Nilemdo and Nexlizet, both of which are already approved in other countries, from Esperion (NASDAQ:ESPR) in May. The November 2025 Health Canada approval of LDL-cholesterol lowering treatment Nilemdo represents…